Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 52.
Article
Arkenau, H-T;
Italiano, A;
Mak, G;
Toulmonde, M;
Baird, RD;
Garcia-Corbacho, J;
Plummer, R;
... Spicer, J; + view all
(2018)
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.
European Journal of Cancer
, 103
pp. 17-23.
10.1016/j.ejca.2018.07.134.
|
|
Bahleda, R;
Meric-Bernstam, F;
Goyal, L;
Tran, B;
He, Y;
Yamamiya, I;
Benhadji, KA;
... Arkenau, H-T; + view all
(2020)
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
Annals of Oncology
10.1016/j.annonc.2020.06.018.
(In press).
|
 |
|
Bendell, JC;
Patel, MR;
Yoshida, K;
Seraj, J;
Weaver, R;
Lemech, C;
Todaro, TG;
... Arkenau, H-T; + view all
(2016)
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
Cancer Chemother Pharmacol
, 77
(6)
pp. 1275-1283.
10.1007/s00280-016-3031-9.
|
|
|
Bono, P;
Massard, C;
Peltola, KJ;
Azaro, A;
Italiano, A;
Kristeleit, RS;
Curigliano, G;
... Rodon, JA; + view all
(2020)
Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours.
ESMO Open
, 5
(6)
, Article e001081. 10.1136/esmoopen-2020-001081.
|
|
|
Bortolomeazzi, M;
Keddar, MR;
Montorsi, L;
Acha-Sagredo, A;
Benedetti, L;
Temelkovski, D;
Choi, S;
... Ciccarelli, FD; + view all
(2021)
Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
Gastroenterology
10.1053/j.gastro.2021.06.064.
(In press).
|
|
|
Brown, NF;
Williams, M;
Arkenau, H-T;
Fleming, RA;
Tolson, J;
Yan, L;
Zhang, J;
... Mulholland, P; + view all
(2018)
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [¹¹C]GSK2256098.
Neuro-Oncology
, 20
(12)
pp. 1634-1642.
10.1093/neuonc/noy078.
|
|
Chatterjee, M;
Turner, DC;
Felip, E;
Lena, H;
Cappuzzo, F;
Horn, L;
Garon, EB;
... Flotten, O; + view all
(2016)
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
Annals of Oncology
, 27
(7)
pp. 1291-1298.
10.1093/annonc/mdw174.
|
|
Chau, I;
Penel, N;
Soriano, AO;
Arkenau, HT;
Cultrera, J;
Santana-Davila, R;
Calvo, E;
... Fuchs, CS; + view all
(2020)
Ramucirumab in combination with pembrolizumab in treatment-naïve advanced gastric or gej adenocarcinoma: Safety and antitumor activity from the phase 1a/b jvdf trial.
Cancers
, 12
(10)
, Article 2985. 10.3390/cancers12102985.
|
|
|
Choueiri, TK;
Plimack, E;
Arkenau, H-T;
Jonasch, E;
Heng, DYC;
Powles, T;
Frigault, MM;
... Pal, SK; + view all
(2017)
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Journal of Clinical Oncology
, 35
(26)
pp. 2993-3001.
10.1200/JCO.2017.72.2967.
|
|
|
Chung, HC;
Arkenau, H-T;
Lee, J;
Rha, SY;
Oh, D-Y;
Wyrwicz, L;
Kang, Y-K;
... Safran, H; + view all
(2019)
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
Journal for ImmunoTherapy of Cancer
, 7
, Article 30. 10.1186/s40425-019-0508-1.
|
|
|
de Bono, JS;
Concin, N;
Hong, DS;
Thistlethwaite, FC;
Machiels, J-P;
Arkenau, H-T;
Plummer, R;
... Lassen, U; + view all
(2019)
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
Lancet Oncology
, 20
(3)
pp. 383-393.
10.1016/S1470-2045(18)30859-3.
|
|
Dirix, LY;
Takacs, I;
Jerusalem, G;
Nikolinakos, P;
Arkenau, H-T;
Forero-Torres, A;
Boccia, R;
... Hamilton, EP; + view all
(2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Breast Cancer Research and Treatment
, 167
(3)
pp. 671-686.
10.1007/s10549-017-4537-5.
|
|
|
Drilon, A;
Siena, S;
Dziadziuszko, R;
Barlesi, F;
Krebs, MG;
Shaw, AT;
de Braud, F;
... Doebele, RC; + view all
(2020)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
The Lancet Oncology
, 21
(2)
pp. 261-270.
10.1016/S1470-2045(19)30690-4.
|
|
Fontana, E;
Arkenau, H-T;
(2020)
Oncology clinical trials during the COVID-19 outbreak: Lessons learnt during the crisis and future opportunities.
Cancer Treatment Reviews
, 88
, Article 102047. 10.1016/j.ctrv.2020.102047.
|
|
|
Formica, V;
Doldo, E;
Antonetti, FR;
Nardecchia, A;
Ferroni, P;
Riondino, S;
Morelli, C;
... Roselli, M; + view all
(2017)
Biological and predictive role of ERCC1 polymorphisms in cancer.
Critical Reviews in Oncology/Hematology
, 111
pp. 133-143.
10.1016/j.critrevonc.2017.01.016.
|
|
Forster, MD;
Moschetta, M;
Uccello, M;
Kasenda, B;
Mak, G;
McClelland, A;
Boussios, S;
(2017)
Dynamics of neutrophils to lymphocyte ratio (NLR) predict outcomes of PD-1/PD-L1 blockade.
BioMed Research International
, 2017
, Article 1506824. 10.1155/2017/1506824.
|
|
|
Fostea, RM;
Fontana, E;
Torga, G;
Arkenau, HT;
(2020)
Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma.
Cancers
, 12
(9)
, Article 2599. 10.3390/cancers12092599.
|
|
|
Greystoke, A;
Steele, N;
Arkenau, H-T;
Blackhall, F;
Haris, NM;
Lindsay, CR;
Califano, R;
... Dean, E; + view all
(2017)
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
British Journal of Cancer
, 117
pp. 938-946.
10.1038/bjc.2017.271.
|
 |
|
Harvey, RD;
Aransay, NR;
Isambert, N;
Lee, J-S;
Arkenau, T;
Vansteenkiste, J;
Dickinson, PA;
... Vishwanathan, K; + view all
(2018)
Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.
British Journal of Clinical Pharmacology
, 84
(12)
pp. 2877-2888.
10.1111/bcp.13753.
|
|
Herbst, RS;
Arkenau, HT;
Bendell, J;
Arrowsmith, E;
Wermke, M;
Soriano, A;
Penel, N;
... Paz-Ares, L; + view all
(2020)
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC.
Journal of Thoracic Oncology
, 16
(2)
pp. 289-298.
10.1016/j.jtho.2020.10.004.
|
|
|
Hong, DS;
Concin, N;
Vergote, I;
de Bono, JS;
Slomovitz, BM;
Drew, Y;
Arkenau, H-T;
... Coleman, RL; + view all
(2020)
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Clinical Cancer Research
, 26
(6)
pp. 1220-1228.
10.1158/1078-0432.CCR-19-2962.
|
|
Hughes, A;
Landers, D;
Arkenau, H-T;
Shah, S;
Stephens, R;
Mahal, A;
Simmons, M;
... Royle, J; + view all
(2016)
Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT.
Advances in Therapy
, 33
(6)
pp. 1012-1024.
10.1007/s12325-016-0335-4.
|
|
Ilson, DH;
Tabernero, J;
Prokharau, A;
Arkenau, H-T;
Ghidini, M;
Fujitani, K;
Van Cutsem, E;
... Shitara, K; + view all
(2019)
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
JAMA Oncology
, 6
(1)
, Article e193531.. 10.1001/jamaoncol.2019.3531.
|
|
|
Koch, C;
Schwing, AM;
Herrmann, E;
Borner, M;
Diaz-Rubio, E;
Dotan, E;
Feliu, J;
... Trojan, J; + view all
(2018)
Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.
Oncotarget
, 9
(12)
pp. 10272-10283.
10.18632/oncotarget.23475.
|
|
|
Kopetz, S;
Grothey, A;
Yaeger, R;
Van Cutsem, E;
Desai, J;
Yoshino, T;
Wasan, H;
... Tabernero, J; + view all
(2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
The New England Journal of Medicine
, 381
(17)
pp. 1632-1643.
10.1056/NEJMoa1908075.
|
|
Lemech, CR;
Ensell, L;
Paterson, JC;
Eminowicz, G;
Lowe, H;
Arora, R;
Arkenau, H-T;
... Kristeleit, RS; + view all
(2016)
Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer.
Oncology
, 91
(1)
pp. 48-54.
10.1159/000445999.
|
|
Lin, CC;
Arkenau, HT;
Lu, S;
Sachdev, J;
de Castro Carpeño, J;
Mita, M;
Dziadziuszko, R;
... Weiss, GJ; + view all
(2019)
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.
British Journal of Cancer
, 121
pp. 131-138.
10.1038/s41416-019-0503-9.
|
|
|
Mak, G;
Moschetta, M;
Arkenau, H-T;
(2016)
Reporting incidental germline variants in the context of day-to-day somatic genomic profiling.
Annals of Oncology
, 27
(5)
pp. 758-759.
10.1093/annonc/mdw078.
|
|
Mak, G;
Soria, J-C;
Blagden, SP;
Plummer, R;
Fleming, RA;
Nebot, N;
Zhang, J;
... Arkenau, H-T; + view all
(2019)
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
British Journal of Cancer
(120)
pp. 975-981.
10.1038/s41416-019-0452-3.
|
|
|
Mansoor, W;
Arkenau, H-T;
Alsina, M;
Shitara, K;
Thuss-Patience, P;
Cuffe, S;
Dvorkin, M;
... Van Cutsem, E; + view all
(2021)
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
Gastric Cancer
10.1007/s10120-021-01156-x.
(In press).
|
|
|
Mateo, J;
Ganji, G;
Lemech, C;
Burris, HA;
Han, S-W;
Swales, K;
Decordova, S;
... Arkenau, H-T; + view all
(2017)
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.
Clinical Cancer Research
, 23
(19)
pp. 5981-5992.
10.1158/1078-0432.CCR-17-0725.
|
|
|
Moore, DA;
Kushnir, M;
Mak, G;
Winter, H;
Curiel, T;
Voskoboynik, M;
Moschetta, M;
... Arkenau, HT; + view all
(2019)
Prospective analysis of 895 patients on a UK Genomics Review Board.
ESMO Open
, 4
(2)
, Article e000469. 10.1136/esmoopen-2018-000469.
|
|
|
Moreno, V;
Greil, R;
Yachnin, J;
Majem, M;
Wermke, M;
Arkenau, HT;
Basque, JR;
... Giovannini, M; + view all
(2021)
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.
Clinical Therapeutics
10.1016/j.clinthera.2021.04.006.
|
|
|
Morschhauser, F;
Machiels, J-P;
Salles, G;
Rottey, S;
Rule, SAJ;
Cunningham, D;
Peyrade, F;
... Awada, A; + view all
(2020)
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Molecular Cancer Therapeutics
, 19
(2)
pp. 468-478.
10.1158/1535-7163.MCT-19-0466.
|
|
Moschetta, M;
Mak, G;
Hauser, J;
Davies, C;
Uccello, M;
Arkenau, HT;
(2017)
Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.
Experimental Hematology & Oncology
, 6
(1)
, Article 1. 10.1186/s40164-016-0061-2.
|
|
|
Mueller, V;
Wardley, A;
Paplomata, E;
Hamilton, E;
Zelnak, A;
Fehrenbacher, L;
Jakobsen, E;
... Gelmon, K; + view all
(2021)
Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
European Journal of Cancer
, 153
pp. 223-233.
10.1016/j.ejca.2021.05.025.
|
|
|
Naing, A;
Thistlethwaite, F;
De Vries, EGE;
Eskens, FALM;
Uboha, N;
Ott, PA;
Lorusso, P;
... Spira, A; + view all
(2021)
CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Journal for ImmunoTherapy of Cancer
, 9
(7)
, Article e002447. 10.1136/jitc-2021-002447.
|
|
|
Nordstrom, BL;
Oguz, M;
Chu, BC;
Ouwens, M;
Arkenau, H-T;
Klein, AB;
(2020)
Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison.
Journal of Comparative Effectiveness Research
, 9
(3)
pp. 191-199.
10.2217/cer-2019-0163.
|
|
|
O'Donnell, PH;
Arkenau, HT;
Sridhar, SS;
Ong, M;
Drakaki, A;
Spira, A;
Zhang, J;
... Friedlander, T; + view all
(2020)
Patient‐reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose‐escalation study 1108.
Cancer
, 126
(2)
pp. 432-443.
10.1002/cncr.32532.
|
|
Perez-Gracia, JL;
Awada, A;
Calvo, E;
Amaral, T;
Arkenau, H-T;
Gruenwald, V;
Bodoky, G;
... Douillard, J-Y; + view all
(2020)
ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy.
ESMO Open
, 5
(3)
, Article e000662. 10.1136/esmoopen-2019-000662.
|
|
|
Perry, N;
Moss, S;
Dixon, S;
Milner, S;
Mokbel, K;
Lemech, C;
Arkenau, H-T;
... Pinker, K; + view all
(2020)
Mammographic Breast Density and Urbanization: Interactions with BMI, Environmental, Lifestyle, and Other Patient Factors.
Diagnostics
, 10
(6)
, Article 418. 10.3390/diagnostics10060418.
|
|
|
Plesner, T;
Arkenau, H-T;
Gimsing, P;
Krejcik, J;
Lemech, C;
Minnema, MC;
Lassen, U;
... Richardson, PG; + view all
(2016)
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Blood
, 128
(14)
pp. 1821-1828.
10.1182/blood-2016-07-726729.
|
|
|
Plesner, T;
Arkenau, HT;
Gay, F;
Minnema, MC;
Boccadoro, M;
Moreau, P;
Cavenagh, J;
... Richardson, PG; + view all
(2019)
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.
British Journal of Haematology
, 186
(3)
e35-e39.
10.1111/bjh.15879.
|
|
Plummer, R;
Dean, E;
Arkenau, HT;
Redfern, C;
Spira, AI;
Melear, JM;
Chung, KY;
... Shapiro, GI; + view all
(2022)
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Lung Cancer
, 163
pp. 19-26.
10.1016/j.lungcan.2021.11.011.
|
|
|
Powles, T;
O'Donnell, PH;
Massard, C;
Arkenau, H-T;
Friedlander, T;
Hoimes, CJ;
Lee, JL;
... Hahn, NM; + view all
(2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. Updated Results From a Phase 1/2 Open-label Study.
JAMA Oncology
, 3
(9)
, Article e172411. 10.1001/jamaoncol.2017.2411.
|
|
Shah, MA;
Kojima, T;
Hochhauser, D;
Enzinger, P;
Raimbourg, J;
Hollebecque, A;
Lordick, F;
... Kato, K; + view all
(2019)
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. The Phase 2 KEYNOTE-180 Study.
JAMA Oncology
, 5
(4)
pp. 546-550.
10.1001/jamaoncol.2018.5441.
|
|
Soria, JC;
Gan, HK;
Blagden, SP;
Plummer, R;
Arkenau, HT;
Ranson, M;
Evans, TRJ;
... Millward, M; + view all
(2016)
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Annals of Oncology
, 27
(12)
pp. 2268-2274.
10.1093/annonc/mdw427.
|
|
|
Tabernero, J;
Alsina, M;
Shitara, K;
Doi, T;
Dvorkin, M;
Mansoor, W;
Arkenau, H-T;
... Ilson, DH; + view all
(2020)
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Gastric Cancer
10.1007/s10120-020-01053-9.
|
|
|
Tabernero, J;
Grothey, A;
Van Cutsem, E;
Yaeger, R;
Wasan, H;
Yoshino, T;
Desai, J;
... Kopetz, S; + view all
(2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Journal of Clinical Oncology
, 39
(4)
pp. 273-284.
10.1200/JCO.20.02088.
|
|
|
Uccello, M;
Moschetta, M;
Mak, G;
Alam, T;
Henriquez, CM;
Arkenau, H-T;
(2018)
Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).
Current Oncology
, 25
(1)
e90-e94.
10.3747/co.25.3708.
|
|
|
van der Noll, R;
Jager, A;
Ang, JE;
Marchetti, S;
Mergui-Roelvink, MWJ;
de Bono, JS;
Lolkema, MP;
... Schellens, JHM; + view all
(2020)
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
Investigational New Drugs
, 38
pp. 1096-1107.
10.1007/s10637-019-00857-6.
|
|
van der Noll, R;
Jager, A;
Ang, JE;
Marchetti, S;
Mergui-Roelvink, MWJ;
Lolkema, MP;
de Jonge, MJA;
... Schellens, JHM; + view all
(2020)
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
Investigational New Drugs
, 38
pp. 1117-1128.
10.1007/s10637-019-00856-7.
|
